Specialty code 183500000X · Roseville, CA
NPI
1447630025
Since 2015
Specialty
Specialty code 183500000X
Code 183500000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
1600 Eureka Rd
Roseville, CA, 95661
Phone (916) 784-4000
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$10.3M
1,248 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Jiahui Chen prescribed most often to Medicare patients was Abiraterone Acetate, with 467 prescriptions and refills. In total Jiahui Chen wrote 1,248 Medicare prescriptions that cost $10.3M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-06-09.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Abiraterone Acetate Generic | 467 | 485 | 100 | $71K |
| Brukinsa Zanubrutinib | 109 | 109 | 25 | $1.2M |
| Tagrisso Osimertinib Mesylate | 108 | 108 | 23 | $1.9M |
| Imatinib Mesylate Generic | 100 | 102 | 17 | $5,346 |
| Ibrance Palbociclib | 55 | 55 | 17 | $827K |
| Verzenio Abemaciclib | 39 | 39 | Under 11 | $721K |
| Kisqali Ribociclib Succinate | 36 | 36 | Under 11 | $509K |
| Jakafi Ruxolitinib Phosphate | 28 | 28 | Under 11 | $379K |
| Cabometyx Cabozantinib S-Malate | 28 | 28 | 11 | $596K |
| Alecensa Alectinib Hcl | 28 | 30 | Under 11 | $535K |
| Tabrecta Capmatinib Hydrochloride | 27 | 31 | Under 11 | $448K |
| Bosulif Bosutinib | 19 | 19 | Under 11 | $289K |
| Calquence Acalabrutinib Maleate | 16 | 16 | Under 11 | $65K |
| Pazopanib Hcl Generic | 15 | 15 | Under 11 | $92K |
| Everolimus Generic | 15 | 15 | Under 11 | $6,361 |
Brand drugs: 647 claims; generic drugs: 601 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Jiahui Chen were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.